Möchten Sie immer auf dem neuesten Stand bleiben?

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion...

Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The...

Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...

Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma...

Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief...

Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...

Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The...

August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to...

Company Announcement Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in operating profit excluding acquisition and...

Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development...